Compare · STVN vs SYK
STVN vs SYK
Side-by-side comparison of Stevanato Group S.p.A. (STVN) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both STVN and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $125.43B, about 25.6x STVN ($4.90B).
- Over the past year, STVN is down 24.5% and SYK is down 10.8% - SYK leads by 13.8 points.
- SYK has been more active in the news (5 items in the past 4 weeks vs 1 for STVN).
- SYK has more recent analyst coverage (25 ratings vs 20 for STVN).
- Company
- Stevanato Group S.p.A.
- Stryker Corporation
- Price
- $16.22-0.12%
- $327.50-0.63%
- Market cap
- $4.90B
- $125.43B
- 1M return
- +13.82%
- -0.03%
- 1Y return
- -24.54%
- -10.77%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 5
- Recent ratings
- 20
- 25
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest STVN
- Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
- SEC Form 3 filed by new insider Santel Luciano
- SEC Form 3 filed by new insider Magistretti Elisabetta
- SEC Form 3 filed by new insider Flynn Karen
- SEC Form 3 filed by new insider Federici William J
- SEC Form 3 filed by new insider Spinazzi Alvise
- SEC Form 3 filed by new insider Morel Donald E Jr
- SEC Form 3 filed by new insider Stevanato Franco
- Amendment: SEC Form 3 filed by new insider Stevanato Sergio
- SEC Form 3 filed by new insider Lin Sue-Jean
Latest SYK
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Leerink Partners initiated coverage on Stryker with a new price target
- Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
- Amendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Stryker to announce financial results for its first quarter of fiscal year 2026
- Stryker names Nick Mead Vice President, Investor Relations
- Amendment: SEC Form SCHEDULE 13G/A filed by Stryker Corporation
- SEC Form 4 filed by Stiles Spencer S
- SEC Form 4 filed by Pierce James Andrew